An insight into the life of p53: A protein coping with many functions! Review of the 9th p53 Workshop, Crete, May 9-13, 1998

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1378, Issue 3, 1998, Pages

  Almog, Nava ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53;

APOPTOSIS; CONFERENCE PAPER; DNA DAMAGE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN SYNTHESIS REGULATION; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE;

EID: 0032569933     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0304-419x(98)00024-9     Document Type: Conference Paper

References (57)

1. Linzer D.I.H., Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 17:1979;43-52.
2. Lane D., Crawford L. T antigen is bound to a host protein in SV40-transformed cells. Nature. 278:1979;261-263.
3. Levine J.A. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
4. Almog N., Rotter V. Involvement of p53 in cell differentiation and development. Biochim. Biophys. Acta. 1333:1997;F1-F27.
5. Hansen R., Oren M. p53-from inductive signal to cellular effect. Curr. Opin. Genet. Dev. 7:1997;46-51.
6. Harris C.C. p53 Tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis. 17:1998;1187-1198.
7. Lane D.P., Hall P.A. MDM2-arbiter of p53's destruction. Trends Biochem. Sci. 22:1997;372-374.
8. Rotter V. p53, a transformation-related cellular encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. Proc. Natl. Acad. Sci. USA. 80:1983;2613-2617.
9. Harris C.C. The 1995 Walter Hubert Lecture - Molecular epidemiology of human cancer: insights from the mutational analysis of p53 tumor suppressor gene. Br. J. Cancer. 73:1996;261-269.
10. S.P. Hussain, C.C. Harris, Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes, Cancer Res., in press.
11. Almog N., Peled A., Li R., Schwartz D., Wolkowicz R., Goldfinger N., Huiping P., Rotter V. The murine C-terminal alternatively spliced p53 form induces attenuated apoptosis in myeloid cells. Mol. Cell. Biol. 17:1997;713-722.
12. Neil J.C., Cameron E.R., Baxter E.W. p53 and tumour viruses: catching the guardian off-guard. Trends Microbiol. 5:1997;115-120.
13. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:1994;346-355.
14. Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild type-p53 activity. EMBO J. 12:(2):1993;461-468.
15. Momand J., Zambetti G.P., Olson C.D., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
16. Haupt Y., Maya R., Kazak A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 387:1997;296-299.
17. Kubbutat M.H.G., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 387:1997;299-303.
18. Kussie P.H., Gorina S., Marechal V., Elenbass B., Moreau J., Levine A.J., Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 274:1997;948-953.
19. Roth J., Dobbelstein M., Freedman D.A., Shenk T., Levine A.J. Nuclear-cytoplasmatic shuttling of the hmd2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17:(2):1998;554-564.
20. Shieh S.-Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:1997;325-334.
21. Siliciano J.D., Canman C.E., Taya Y., Sakaguchi K., Appella E., Kastan M.B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11:1997;3471-3481.
22. Pomerantz J., Schreiber-Agus N., Liegeois N.J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H.-W., Cordon-Cardo C., DePinho R.A. The INK4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:1998;713-723.
23. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:1998;725-734.
24. Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., Tagle D., Smith S., Uziel T., Sfez S., Asjkenazi M., Pecker I., Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A., Sartiel A., GAtti R.A., Chessa L., Sanal O., Lavin M.F., Jaspers N.G., Taylor M.A., Arlett C.F., Miki T., Weismann S.M., Lovett M., Collins F.S., Shiloh Y. A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science. 268:1995;1749-1753.
25. Savitsky K., Sfez S., Tagle D.A., Ziv Y., Sartiel A., Collins F.S., Shiloh Y., Rotman G. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum. Mol. Genet. 4:1995;2025-2032.
26. S. Banin, L. Moyal, S.-Y. Shieh, C.W. Anderson, L. Chessa, N.I. Smorodinsky, C. Prives, Y. Shiloh, Y. Ziv, DNA damage-enhanced phosphorylation of p53 by ATM, submitted for publication.
27. Meek D.W. Multisite phosphorylation and the integration of stress signals at p53. Cell Signal. 10:1998;159-166.
28. Knippschild U., Milne D.M., Campbell L.R., DeMaggio A.J., Christenson E., Hoekstra M.F., Meek D.W. p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs. Oncogene. 15:1997;1727-1736.
29. Waterman M.J.F., Stavridi E.S., Waterman J.L.F., Halazonetis T.D. ATM-dependent activation of p53 involves dephosphorylation and association with 14-4-3 proteins. Nat. Genet. 19:1998;175-178.
30. Gu W., Shi X.-L., Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature. 387:1997;819-823.
31. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90:1997;595-606.
32. Lill N.L., Grossman S.R., Ginsberg D., DeCaprio J., Livingston D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature. 387:1997;823-827.
33. Ko J.L., Prives C. p53: puzzle and paradigm. Genes Dev. 10:1996;1054-1072.
34. Hupp T.R., Lane D.P. Allosteric activation of latent p53 tetramers. Curr. Biol. 4:1994;865-875.
35. Wolkowicz R., Rotter V. The DNA binding regulatory domain of p53: see the C. Pathol. Biol. 45:1997;785-796.
36. Jayaraman L., Murthy K.G.K., Zhu C., curran T., Xanthoudakis S., Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev. 11:1997;558-570.
37. Jayaraman L., Moorthy N.C., Murthy K.G.K., Manley J.L., Bustin M., Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 12:1998;462-472.
38. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.-C., Valent A., Minty A., Chalon P., Lelias J.-M., Dumont X., Ferrara P., McKeon F., Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:1997;809-819.
39. Jost C.A., Marin M.C., Kaelin W.G. Jr. p73 is a human p53-related protein that can induce apoptosis. Nature. 389:1997;191-194.
40. Schmale H., Bamberger C. A novel protein with strong homology to the tumor suppressor p53. Oncogene. 15:1997;1363-1367.
41. Lowe S.W., Jacks T., Housman D.E., Ruley H.E. Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc. Natl. Acad. Sci. USA. 91:1994;2026-2030.
42. Debbas M., White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Gene Dev. 7:(4):1993;546-554.
43. Hermeking H., Eick D. Mediation of c-myc-induced apoptosis by p53. Science. 265:1994;2091-2093.
44. Reisman D., Elkind N.B., Roy B., Beamon J., Rotter V. C-myc transactivates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ. 4:1993;57-65.
45. Serrano M., Lin A.W., McCurrach M.E., Beach D., Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:1997;593-602.
46. Sheikh M.S., Burns T.F., Huang Y., Wu G.S., Amundson S., Brooks K.S., Fornace A.J., El-Deiry W.S. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic and tumor necrosis factor alpha. Cancer Res. 58:1998;1593-1598.
47. Wu G.S., Burns T.F., McDonald E.R. III, Jiang W., Meng R., Drantz I.D., Kao G., Gan D., Zhou J.-Y., Muschel R., Hamilton S.R., Spinner N.B., Markowitz S., Wu G., El-Deiry W.S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17:1997;141-143.
48. Muller M., Strand S., Hug H., Heinemann E.M., Walczak H., Hofmann W.J., Stremmel W., Krammer P.H., Galle P.R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99:1997;403-413.
49. de Oca Luna R.M., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature. 378:1995;203-206.
50. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in mdm-2 deficient mice by absence of p53. Nature. 378:1995;206-208.
51. Peled A., Zipori D., Rotter V. Cooperation between p53-dependent and p53-independent apoptotic pathway of myeloid cells. Cancer Res. 56:1996;2148-2156.
52. R. Li, P.D. Sutphin, D. Schwartz, D. Matas, N. Almog, R. Wolkowicz, N. Goldfinger, P. Huiping, M. Prokocimer, V. Rotter, Mutant p53 protein expression interferes with p53-independent apoptotic pathways, Oncogene, in press.
53. Lanni J.S., Lowe S.W., Licitra E.J., Liu J.O., Jacks T. p53-independent apoptosis induced by paclitaxel through an indirect mechanism. Proc. Natl. Acad. Sci. USA. 94:1997;9679-9683.
54. Nigro J.M., Aldape K.D., Hess S.M., Tlsty T.D. Cellular adhesion regulates p53 protein levels in primary human keratinocytes. Cancer Res. 57:1997;3635-3639.
55. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 6:1997;639-645.
56. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:1996;373-376.
57. Selivanova G., Iotsova V., Okan I., Fritsche M., Strome M., Groner B., Graftstrom R.C., Wiman K.G. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 3:1997;632-638.